Postema P T, De Herder W W, Reubi J C, Oei H Y, Kwekkeboom D J, Bruining H J, Bonjer J, van Toor H, Hennemann G, Krenning E P
Department of Internal Medicine III, University Hospital, Rotterdam, The Netherlands.
Digestion. 1996;57 Suppl 1:36-7. doi: 10.1159/000201391.
8 patients with papillary cancer (4 with metastases, 4 in remission), 7 follicular cancer patients (6 with metastases), 2 patients with anaplastic thyroid cancer and 4 other non-medullary thyroid cancer patients all received an intravenous bolus injection of 220 MBq [111In-DTPA-D-Phe1]octreotide. Planar anterior and posterior gamma camera images of head-neck, chest and abdomen were obtained 24 and 48 h after injection. All primary cancers showed [111In-DTPA-D-Phe1] octreotide uptake; none occurred in patients in remission. The results were compared with conventional radio-iodine scintigraphy in patients with metastasised, differentiated thyroid cancer.
8例乳头状癌患者（4例有转移，4例处于缓解期）、7例滤泡状癌患者（6例有转移）、2例间变性甲状腺癌患者以及4例其他非髓样甲状腺癌患者均接受了220 MBq[111铟 - DTPA - D - 苯丙氨酸1]奥曲肽的静脉推注。在注射后24小时和48小时获得了头颈部、胸部和腹部的平面前位和后位γ相机图像。所有原发性癌症均显示[111铟 - DTPA - D - 苯丙氨酸1]奥曲肽摄取；缓解期患者未出现摄取情况。将结果与转移性分化型甲状腺癌患者的传统放射性碘闪烁显像结果进行了比较。
